Among the 20 patients who started ponatinib because of intolerance to previous TKIs, MMR was achieved as best response by 9 (64%) CML and 4 (67%) Ph+ ALL patients and 1 (7%) CML patient achieved BCR-ABL1 mRNA ≤1% (Fig. 4). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.